Study Explains Checkpoint Inhibitors’ Efficacy in PD-L1 Negative Tumors
News
Immune checkpoint inhibitors targeting the PD-L1 molecule appear to activate immune cells called natural killer (NK) cells, a new study says. This finding may explain why some tumors are responsive ... Read more